← Back to Clinical Trials
Recruiting NCT05146180

NCT05146180 Interest of Parametric Positron Emission Imaging in the Diagnosis of Infections on Cardiac Valve Prosthesis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05146180
Status Recruiting
Phase
Sponsor Centre Henri Becquerel
Condition Endocarditis
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2022-02-24
Primary Completion 2026-12-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Parametric positron emission computed tomography

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2022-02-24 with a primary completion date of 2026-12-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objective of this study is to determine if early parametric positron emission computed tomography is useful to diagnose cardiac prosthetic valve infections.

Eligibility Criteria

Inclusion Criteria: * Age superior to18 years, * Effective contraception for women of childbearing age or negative pregnancy test on the day of the exam * Good general condition. WHO ≤ 1 * Suspicion of endocarditis on a prosthetic heart valve implanted more than 3 months ago * Labeled polynuclear scintigraphy performed within a maximum of 15 days before positron emission computed tomography * Standard positron emission computed tomography planned as part of the extension assessment * Informed and signed consent before any specific study procedure. * Patient affiliated to the social security system Exclusion Criteria: * Presence of an active cancer in the previous three years * Pregnancy or breastfeeding * Poorly controlled diabetic patients * Protected adults (under guardians or curators) * Impossible decubitus (orthopnea, ...), * Hypersensitivity to FDG or to one of the excipients of the radiopharmaceutical.

Contact & Investigator

Central Contact

Mathieu Chastan, MD

✉ mathieu.chastan@chb.unicancer.fr

📞 +33276673032

Principal Investigator

Mathieu Chastan, MD

PRINCIPAL INVESTIGATOR

Centre Henri Becquerel

Frequently Asked Questions

Who can join the NCT05146180 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Endocarditis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05146180 currently recruiting?

Yes, NCT05146180 is actively recruiting participants. Contact the research team at mathieu.chastan@chb.unicancer.fr for enrollment information.

Where is the NCT05146180 trial being conducted?

This trial is being conducted at Rouen, France.

Who is sponsoring the NCT05146180 clinical trial?

NCT05146180 is sponsored by Centre Henri Becquerel. The principal investigator is Mathieu Chastan, MD at Centre Henri Becquerel. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology